Kidney biotech R1's $78m debut, and other biofinancings Biofinancing values have tailed off a bit after a strong start to 2026, but March has seen $50m+ rounds for R1, Crossbow, Excalipoint, and Prolium.

After a strong start to the year, the value of #biotech #financings has tailed off a little, but March has seen a clutch of $50 million-plus rounds for #R1, #Crossbow, #Excalipoint, and #Prolium.

pharmaphorum.com/news/kidney-...

ILiAD bags $115m for pertussis vaccine, and other financings This week's biofinancings include a nine-figure round for ILiAD, with Quantx Bio, Aerska, Galux, and Pandorum Technologies also raising new funds.

#ILiADBiotechnologies leads this week's round-up of new private #financings in the #biopharma sector, with a $115 million Series B #investment that will be used to test a new type of #whoopingcough (Bordetella pertussis) #vaccine.

pharmaphorum.com/news/iliad-b...

Parabilis scores $305m in bumper biofinancing week Money has flooded into biotechs this week, with Parabilis raising $305m and five other start-ups closing nine-figure private rounds.

January has started with a bang for private #biotech #financings, with this week's haul including an impressive $305 million Series F for #ParabilisMedicines.

pharmaphorum.com/news/parabil...

Ambros' $125m for pain disorder drug, and other financings Our latest crop of biofinancings has nine-figure rounds for Ambros, Atavistik, Orum, and Addition, with Link Cell and Aeovian also raising new funds.

Our round-up of #financings in the biotech arena this week is led by a $125 million Series A for #AmbrosTherapeutics, a start-up formed to develop a drug for a rare #paindisorder that is already on the market in Italy.

Braveheart, AAVantgarde rounds head recent biofinancings Our latest crop of biotech financings has nine-figure rounds for Braveheart and AAVantgarde, with Azalea Therapeutics and NEOK Bio also raising funds.

Our round-up of #biotech #financings is led this week by #BraveheartBio, a San Francisco biotech that has launched with $185 million, a lead drug for hypertrophic #cardiomyopathy (HCM), and Biogen CEO Chris Viehbacher as its chair.

pharmaphorum.com/news/bravehe...

Original post on globalfintechseries.com

DeFi Development Corp. Expands Treasury Accelerator to Deploy Company Balance Sheet into Global DATs DeFi Development Corp. the first public company with a treasury strategy built to accumulate and...

#DeFi #News #convertible #structures #debt […]

[Original post on globalfintechseries.com]

Granite Bio makes $100m debut, and other bio financings Our round-up of recent biotech financings includes rounds for Granite Bio, Biolinq, Etiome, Grove Biopharma, and Synthetic Design Lab.

NEWS: Swiss start-up #GraniteBio has carved out $100 million in a pair of #financings for its pipeline of potentially first-in-class #antibodies for autoimmune diseases.

pharmaphorum.com/news/granite...

Original post on therealdeal.com

Adam Neumann lands $155M loan for Miami Flow House condos Adam Neumann scored a $155 million loan...

therealdeal.com/miami/2025/04/09/adam-ne...

#Condo #Market #Condos #Downtown #Miami #financings #Flow #Miami […]

[Original post on therealdeal.com]

Original post on therealdeal.com

Baron scores $206M construction loan for 661-unit apartment project in Hialeah Baron Property Gro...

therealdeal.com/miami/2025/03/20/baron-p...

#Baron #Property #Group #Construction #Loans […]

[Original post on therealdeal.com]

Original post on therealdeal.com

Baron scores $206M construction loan for 661-unit apartment project in Hialeah Baron Property Gro...

therealdeal.com/miami/2025/03/20/baron-p...

#Construction #Loans #financings #Hialeah #Miami-Dade […]

[Original post on therealdeal.com]